2023
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
Lea A, Leyden W, Sofrygin O, Marafino B, Skarbinski J, Napravnik S, Agil D, Augenbraun M, Benning L, Horberg M, Jefferson C, Marconi V, Park L, Gordon K, Bastarache L, Gangireddy S, Althoff K, Coburn S, Gebo K, Lang R, Williams C, Silverberg M. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout. Clinical Infectious Diseases 2023, 76: 1727-1734. PMID: 36861341, PMCID: PMC10209434, DOI: 10.1093/cid/ciad084.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAdjusted risk ratioCOVID-19 hospitalizationMechanical ventilationTenofovir useHIV statusAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSevere coronavirus disease 2019 (COVID-19) outcomesSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) outcomesHuman immunodeficiency virus statusCohort of PWHCD4 cell countCharlson Comorbidity IndexCoronavirus 2 infectionHIV RNA levelsUnited States cohortBody mass indexCOVID-19 severityCOVID-19 vaccine availabilityReal-world analysisTenofovir exposureComorbidity indexMass index
2022
1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. 1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS). Open Forum Infectious Diseases 2022, 9: ofac492.1096. PMCID: PMC9752102, DOI: 10.1093/ofid/ofac492.1096.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyDTG-based regimensAging Cohort StudyViiV HealthcareCohort studyOlder peopleART-experienced individualsCD4 cell countEnd of studyRegimen discontinuationRegimen initiationAntiretroviral regimensVirologic failureART-naïveMultiple comorbiditiesHIV managementOlder PLWHPLWHTreatment responseTreatment statusRegimensTreatment experienceDolutegravirRaltegravirCell countAnalysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factors
2016
Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study
Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D, Rodriguez-Barradas MC, Gibert C, Goetz MB, Bedimo R, Park LS, Dubrow R. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. The Lancet HIV 2016, 4: e67-e73. PMID: 27916584, PMCID: PMC5444465, DOI: 10.1016/s2352-3018(16)30215-6.Peer-Reviewed Original ResearchConceptsCD4/CD8 ratioBacterial pneumonia episodesLung cancerCD8 ratioPneumonia episodesCohort studyHIV infectionUse disordersCumulative exposureLower CD4/CD8 ratioLow CD4 cell countsHepatitis C virus infectionVeterans Aging Cohort StudyChronic obstructive pulmonary diseaseAntiretroviral therapy eraAverage cumulative exposureDysfunctional immune activationHIV RNA concentrationIncident lung cancerLarge HIV cohortC virus infectionCD4 cell countObstructive pulmonary diseaseAging Cohort StudyInfectious risk factorsThe impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy
Edelman E, Gordon K, Tate J, Becker W, Bryant K, Crothers K, Gaither, Gibert C, Gordon A, Marshall B, Rodriguez‐Barradas M, Samet J, Skanderson M, Justice A, Fiellin D. The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy. HIV Medicine 2016, 17: 728-739. PMID: 27186715, PMCID: PMC5053822, DOI: 10.1111/hiv.12377.Peer-Reviewed Original ResearchConceptsCD4 cell countBaseline CD4 cell countCell countPrescribed opioidsImmunosuppressive propertiesVeterans Aging Cohort Study (VACS) dataCD4 cell count recoveryAntiretroviral therapy responseCell count recoveryShort-term opioidsViral load suppressionCohort study dataOverall disease severityYear of initiationPrimary independent variableOpioid durationAntiretroviral therapyCount recoveryComorbid conditionsPharmacy dataOpioid propertiesTherapy responseOpioidsPatientsHIV